NPB-01 ( DrugBank: - )

---

3 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
14	Chronic inflammatory demyelinating polyneuropathy	2
162	Pemphigoid	2

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01845584 (ClinicalTrials.gov)	May 2013	26/4/2013	Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.	NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.	Neuromyelitis Optica Spectrum Disorder	Drug: NPB-01	Nihon Pharmaceutical Co., Ltd	NULL	Completed	20 Years	N/A	All	7	Phase 2	Japan

14. Chronic inflammatory demyelinating polyneuropathy

---

Clinical trials : 175 /  Drugs : 161 - (DrugBank : 41) / Drug target genes : 13 - Drug target pathways : 24

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01824251 (ClinicalTrials.gov)	April 2013	1/4/2013	Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.	NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy.	Chronic Inflammatory Demyelinating Polyneuropathy	Drug: NPB-01	Nihon Pharmaceutical Co., Ltd	NULL	Completed	20 Years	100 Years	Both	49	Phase 3	Japan
2	NCT01827072 (ClinicalTrials.gov)	April 2013	1/4/2013	Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.	NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Multifocal Motor Neuropathy.	Multifocal Motor Neuropathy	Drug: NPB-01	Nihon Pharmaceutical Co., Ltd	NULL	Completed	20 Years	100 Years	Both	13	Phase 3	Japan

162. Pemphigoid

---

Clinical trials : 90 /  Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01408550 (ClinicalTrials.gov)	August 2011	27/7/2011	Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids	NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase III)	Bullous Pemphigoid	Drug: NPB-01;Drug: Placebo	Nihon Pharmaceutical Co., Ltd	NULL	Completed	20 Years	N/A	Both	56	Phase 3	Japan
2	NCT00809822 (ClinicalTrials.gov)	November 2008	11/12/2008	Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.	NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase?).	Bullous Pemphigoid	Drug: NPB-01;Drug: Placebo	Nihon Pharmaceutical Co., Ltd	NULL	Completed	20 Years	N/A	Both	20	Phase 2	Japan

Back to top